Acido zoledronico (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Acido zoledronico" in Italian language version.

refsWebsite

Global rank Italian rank

11nih.gov

4^th place

9^th place

9oadoi.org

799^th place

22^nd place

9doi.org

2^nd place

7^th place

2web.archive.org

1^st place

1agenziafarmaco.gov.it

low place

1,603^rd place

agenziafarmaco.gov.it

AIFA, Agenzia Italiana del farmaco Nota_Informativa_Importante_su_ACLASTA.pdf (PDF), su agenziafarmaco.gov.it, marzo 2010. URL consultato il 24 novembre 2012.

doi.org

dx.doi.org

Lyles K, et al., Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture, in N. Engl. J. Med., vol. 357, n. 18, 2007, p. 1799, DOI:10.1056/NEJMoa074941, PMID 17878149.
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ, Intravenous zoledronic acid in postmenopausal women with low bone mineral density, in N. Engl. J. Med., vol. 346, n. 9, 2002, pp. 653–61, DOI:10.1056/NEJMoa011807, PMID 11870242.
S. Mariani, M. Muraro; F. Pantaleoni; F. Fiore; B. Nuschak; S. Peola; M. Foglietta; A. Palumbo; M. Coscia; B. Castella; B. Bruno, Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma., in Leukemia, vol. 19, n. 4, Apr 2005, pp. 664-70, DOI:10.1038/sj.leu.2403693, PMID 15744346.
A. Munier, V. Gras; M. Andrejak; N. Bernard; MJ. Jean-Pastor; S. Gautier; M. Biour; Z. Massy, Zoledronic Acid and renal toxicity: data from French adverse effect reporting database., in Ann Pharmacother, vol. 39, n. 7-8, Lug-Ago 2005, pp. 1194-7, DOI:10.1345/aph.1E589, PMID 15956222.
JT. Chang, L. Green; J. Beitz, Renal failure with the use of zoledronic acid., in N Engl J Med, vol. 349, n. 17, Oct 2003, pp. 1676-9; discussion 1676-9, DOI:10.1056/NEJM200310233491721, PMID 14573746.
R. Coleman, E. Woodward; J. Brown; D. Cameron; R. Bell; D. Dodwell; M. Keane; M. Gil; C. Davies; R. Burkinshaw; SJ. Houston, Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer., in Breast Cancer Res Treat, vol. 127, n. 2, Jun 2011, pp. 429-38, DOI:10.1007/s10549-011-1429-y, PMID 21394500.
V. Fusco, C. Galassi; A. Berruti; L. Ciuffreda; C. Ortega; G. Ciccone; A. Angeli; O. Bertetto, Osteonecrosis of the jaw after zoledronic acid and denosumab treatment., in J Clin Oncol, vol. 29, n. 17, Jun 2011, pp. e521-2; author reply e523-4, DOI:10.1200/JCO.2011.35.1551, PMID 21537047.
BJ. Edwards, M. Gounder; JM. McKoy; I. Boyd; M. Farrugia; C. Migliorati; R. Marx; S. Ruggiero; M. Dimopoulos; DW. Raisch; S. Singhal, Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw., in Lancet Oncol, vol. 9, n. 12, Dec 2008, pp. 1166-72, DOI:10.1016/S1470-2045(08)70305-X, PMID 19038763.
MH. Abu-Id, Y. Açil; J. Gottschalk; T. Kreusch, [Bisphosphonate-associated osteonecrosis of the jaw]., in Mund Kiefer Gesichtschir, vol. 10, n. 2, Mar 2006, pp. 73-81, DOI:10.1007/s10006-005-0670-0, PMID 16456688.

nih.gov

ncbi.nlm.nih.gov

Lyles K, et al., Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture, in N. Engl. J. Med., vol. 357, n. 18, 2007, p. 1799, DOI:10.1056/NEJMoa074941, PMID 17878149.
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ, Intravenous zoledronic acid in postmenopausal women with low bone mineral density, in N. Engl. J. Med., vol. 346, n. 9, 2002, pp. 653–61, DOI:10.1056/NEJMoa011807, PMID 11870242.
S. Mariani, M. Muraro; F. Pantaleoni; F. Fiore; B. Nuschak; S. Peola; M. Foglietta; A. Palumbo; M. Coscia; B. Castella; B. Bruno, Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma., in Leukemia, vol. 19, n. 4, Apr 2005, pp. 664-70, DOI:10.1038/sj.leu.2403693, PMID 15744346.
A. Munier, V. Gras; M. Andrejak; N. Bernard; MJ. Jean-Pastor; S. Gautier; M. Biour; Z. Massy, Zoledronic Acid and renal toxicity: data from French adverse effect reporting database., in Ann Pharmacother, vol. 39, n. 7-8, Lug-Ago 2005, pp. 1194-7, DOI:10.1345/aph.1E589, PMID 15956222.
C. Ramazzina, Y. Zysset Aschmann; O. Kummer; AE. Rätz Bravo; M. Bodmer, [Zoledronate-associated end stage renal failure and hypocalcaemia]., in Praxis (Bern 1994), vol. 96, n. 17, Apr 2007, pp. 673-6; quiz 677-8, PMID 17491196.
K. Koike, K. Fukami; S. Morishige; T. Hazama; K. Taguchi; R. Ando; M. Nagano; J. Yoshimura; S. Ueda; M. Hashiguchi; K. Tamaki, [Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma]., in Nihon Jinzo Gakkai Shi, vol. 51, n. 5, 2009, pp. 557-62, PMID 19715164.
JT. Chang, L. Green; J. Beitz, Renal failure with the use of zoledronic acid., in N Engl J Med, vol. 349, n. 17, Oct 2003, pp. 1676-9; discussion 1676-9, DOI:10.1056/NEJM200310233491721, PMID 14573746.
R. Coleman, E. Woodward; J. Brown; D. Cameron; R. Bell; D. Dodwell; M. Keane; M. Gil; C. Davies; R. Burkinshaw; SJ. Houston, Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer., in Breast Cancer Res Treat, vol. 127, n. 2, Jun 2011, pp. 429-38, DOI:10.1007/s10549-011-1429-y, PMID 21394500.
V. Fusco, C. Galassi; A. Berruti; L. Ciuffreda; C. Ortega; G. Ciccone; A. Angeli; O. Bertetto, Osteonecrosis of the jaw after zoledronic acid and denosumab treatment., in J Clin Oncol, vol. 29, n. 17, Jun 2011, pp. e521-2; author reply e523-4, DOI:10.1200/JCO.2011.35.1551, PMID 21537047.
BJ. Edwards, M. Gounder; JM. McKoy; I. Boyd; M. Farrugia; C. Migliorati; R. Marx; S. Ruggiero; M. Dimopoulos; DW. Raisch; S. Singhal, Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw., in Lancet Oncol, vol. 9, n. 12, Dec 2008, pp. 1166-72, DOI:10.1016/S1470-2045(08)70305-X, PMID 19038763.
MH. Abu-Id, Y. Açil; J. Gottschalk; T. Kreusch, [Bisphosphonate-associated osteonecrosis of the jaw]., in Mund Kiefer Gesichtschir, vol. 10, n. 2, Mar 2006, pp. 73-81, DOI:10.1007/s10006-005-0670-0, PMID 16456688.

oadoi.org

Lyles K, et al., Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture, in N. Engl. J. Med., vol. 357, n. 18, 2007, p. 1799, DOI:10.1056/NEJMoa074941, PMID 17878149.
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ, Intravenous zoledronic acid in postmenopausal women with low bone mineral density, in N. Engl. J. Med., vol. 346, n. 9, 2002, pp. 653–61, DOI:10.1056/NEJMoa011807, PMID 11870242.
S. Mariani, M. Muraro; F. Pantaleoni; F. Fiore; B. Nuschak; S. Peola; M. Foglietta; A. Palumbo; M. Coscia; B. Castella; B. Bruno, Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma., in Leukemia, vol. 19, n. 4, Apr 2005, pp. 664-70, DOI:10.1038/sj.leu.2403693, PMID 15744346.
A. Munier, V. Gras; M. Andrejak; N. Bernard; MJ. Jean-Pastor; S. Gautier; M. Biour; Z. Massy, Zoledronic Acid and renal toxicity: data from French adverse effect reporting database., in Ann Pharmacother, vol. 39, n. 7-8, Lug-Ago 2005, pp. 1194-7, DOI:10.1345/aph.1E589, PMID 15956222.
JT. Chang, L. Green; J. Beitz, Renal failure with the use of zoledronic acid., in N Engl J Med, vol. 349, n. 17, Oct 2003, pp. 1676-9; discussion 1676-9, DOI:10.1056/NEJM200310233491721, PMID 14573746.
R. Coleman, E. Woodward; J. Brown; D. Cameron; R. Bell; D. Dodwell; M. Keane; M. Gil; C. Davies; R. Burkinshaw; SJ. Houston, Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer., in Breast Cancer Res Treat, vol. 127, n. 2, Jun 2011, pp. 429-38, DOI:10.1007/s10549-011-1429-y, PMID 21394500.
V. Fusco, C. Galassi; A. Berruti; L. Ciuffreda; C. Ortega; G. Ciccone; A. Angeli; O. Bertetto, Osteonecrosis of the jaw after zoledronic acid and denosumab treatment., in J Clin Oncol, vol. 29, n. 17, Jun 2011, pp. e521-2; author reply e523-4, DOI:10.1200/JCO.2011.35.1551, PMID 21537047.
BJ. Edwards, M. Gounder; JM. McKoy; I. Boyd; M. Farrugia; C. Migliorati; R. Marx; S. Ruggiero; M. Dimopoulos; DW. Raisch; S. Singhal, Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw., in Lancet Oncol, vol. 9, n. 12, Dec 2008, pp. 1166-72, DOI:10.1016/S1470-2045(08)70305-X, PMID 19038763.
MH. Abu-Id, Y. Açil; J. Gottschalk; T. Kreusch, [Bisphosphonate-associated osteonecrosis of the jaw]., in Mund Kiefer Gesichtschir, vol. 10, n. 2, Mar 2006, pp. 73-81, DOI:10.1007/s10006-005-0670-0, PMID 16456688.

web.archive.org

Black et al.. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM 2007;356;18;1809-1822. Abstract (archiviato dall'url originale il 19 agosto 2009).
European Medicines Agency - Human medicines - Aclasta, su ema.europa.eu, 15 dicembre 2011. URL consultato il 24 novembre 2012 (archiviato dall'url originale il 25 settembre 2015).